
Eli Lilly: positive results from weekly insulin trials
(CercleFinance.com) - Eli Lilly announces "positive" results from two phase 3 clinical trials (QWINT-1 and QWINT-3) evaluating weekly administration of insulin efsitora alfa in adults with type 2 diabetes compared to daily administration of basal insulins.
The results showed that efsitora is as effective as daily insulin in reducing HbA1c, with a similar safety profile and fewer episodes of hypoglycaemia.
Efsitora could simplify insulin management with a weekly regimen, making life easier for patients. Detailed results will be presented at forthcoming conferences.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The results showed that efsitora is as effective as daily insulin in reducing HbA1c, with a similar safety profile and fewer episodes of hypoglycaemia.
Efsitora could simplify insulin management with a weekly regimen, making life easier for patients. Detailed results will be presented at forthcoming conferences.
Copyright (c) 2024 CercleFinance.com. All rights reserved.